However, the neoadjuvant therapy approach demonstrated in our study may provide an ideal model for addressing the impact of HER2 overexpression on the response to hormone therapy in DCIS in larger clinical trials. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.